# A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

> **NCT05460273** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 119 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan (Dato-DXd)

## Key facts

- **NCT ID:** NCT05460273
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2023-11-07
- **Final completion:** 2026-06-30
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460273, "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05460273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*